Email Updates

You are here

AVAC in the News

  • Someone was blowing a whistle. A crowd with placards surged into the conference room, chanting “PrEP costs pennies, ViiV’s greed kills”. Not an obvious slogan, but everyone in the room knew what it meant. The protesters took over the stage, denouncing “pharma’s greed” at the microphone. On the platform, those whose session had been interrupted smiled, even applauded. “Thank you for your advocacy. Please allow the session to continue,” read prepared slides on the overhead screens.

    August 3, 2022
    The Guardian
  • Someone was blowing a whistle. A crowd with placards surged into the conference room, chanting “PrEP costs pennies, ViiV’s greed kills”. Not an obvious slogan, but everyone in the room knew what it meant. The protesters took over the stage, denouncing “pharma’s greed” at the microphone. On the platform, those whose session had been interrupted smiled, even applauded. “Thank you for your advocacy. Please allow the session to continue,” read prepared slides on the overhead screens.

    August 3, 2022
    The Guardian
  • An injection every two months of the antiretroviral cabotegravir is the most effective way to prevent HIV that the world has ever seen. Making it affordable will depend, in part, on how many generic manufacturers will invest in producing it — and for that, the world must show the promise of markets: millions of otherwise healthy people who will line up at a pharmacy or clinic for a quick injection every two months. The question is: how do you create a market for a product that most of the world has not yet seen?

    August 2, 2022
    aidsmap
  • Antivirals have historically made up the bulk of licenses that allow generic companies to copy innovative drugs for poorer countries. Now, GSK’s ViiV Healthcare is adding the world’s first long-acting HIV prevention med to a patent-sharing program merely seven months into an FDA approval. GSK has signed a licensing deal with the United Nations-backed Medicines Patent Pool (MPP) for its long-acting HIV PrEP drug Apretude, or cabotegravir, the two parties unveiled during the 24th International AIDS Conference.

    July 28, 2022
    Fierce Pharma
  • en years ago this month, the Food and Drug Administration approved a daily pill that was up to 99% effective in preventing infection with HIV, the virus that causes AIDS. Expectations were high that this approach, known as oral pre-exposure prophylaxis (PrEP), could change the course of the AIDS pandemic. It hasn’t. The use of oral PrEP today is stubbornly low, while HIV rates remain tenaciously high.

    July 19, 2022
    Stat
  • On July 16, 2012, the Food and Drug Administration (FDA) approved Truvada for pre-exposure prophylaxis—better known as PrEP—to prevent HIV acquisition. But although uptake has improved over the past decade, PrEP still isn’t reaching everyone at risk for HIV.

    July 16, 2022
    POZ Magazine
  • On July 16, 2012, the Food and Drug Administration (FDA) approved Truvada for pre-exposure prophylaxis—better known as PrEP—to prevent HIV acquisition. But although uptake has improved over the past decade, PrEP still isn’t reaching everyone at risk for HIV. Truvada (TDF/FTC) contains two drugs, tenofovir disoproxil fumarate and emtricitabine, that are widely used for HIV treatment.

    July 16, 2022
    POZ Magazine
  • HIV care has come a long way in the more than 40 years since the Centers for Disease Control and Prevention published the first report of AIDS in June 1981. The combined efforts of researchers, clinicians, public health officials, activists and people living with HIV have led to amazing advances in prevention and treatment. And despite many setbacks, cure research is also making progress.

    June 27, 2022
    POZ Magazine
  • Melb Simiyu, an HIV prevention officer at a support organization for sex workers here, says most of her clients have asked when a drug called CAB-LA will become available. Approved by the US Food and Drug Administration (FDA) in December 2021, the HIV prevention drug could drastically reduce infections among marginalized groups like the one she works with.

    June 24, 2022
    Science
  • Melb Simiyu, an HIV prevention officer at a support organization for sex workers here, says most of her clients have asked when a drug called CAB-LA will become available. Approved by the U.S. Food and Drug Administration (FDA) in December 2021, the HIV prevention drug could drastically reduce infections among marginalized groups like the one she works with. But even though a trial in Uganda and six other sub-Saharan African countries provided data key for FDA’s approval, Africa, still the part of the world hardest hit by HIV, may face a long wait to get the drug at an affordable price.

    June 21, 2022
    Science

Pages